Fisetin shows therapeutic efficacy in CRC via suppressing the PI3K/Akt/mTOR signaling, and fisetin combination with 5‐FU decreased the total number of intestinal tumors in the treatment of PIK3CA‐mutant CRC (Khan et al. 2019). This evidence concerns the gene PIK3CA and intestinal neoplasm.